Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 4,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Depression Clear all
Completed No phase listed Observational

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavior Therapy (CBT), Nonspecific Supportive Therapy (PBO)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

NCT04448327
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
active tVNS, Sham tVNS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)

NCT00463242
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine, paroxetine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Phoenix, Arizona • National City, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate in Alcoholics With Comorbid Anxiety or Depression

NCT00330174
View directory record Official record
Conditions
Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Belmont, Massachusetts • New York, New York • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reactions to Social Media Warning Labels Among Teens and Young Adults

NCT07199660
View directory record Official record
Conditions
Screen Time Exposure
Interventions
Human-developed negative body image warning, Voluntary warning, Human-developed depression and anxiety warning, Human-developed addiction warning, Human-developed sleep warning, Human-developed mental health harms to young people warning, Human-developed warning that social media has not been proven safe, Control message, California's proposed social media warning, Artificial-intelligence-developed depression and anxiety warning, Artificial-intelligence-developed negative body image warning, Artificial-intelligence-developed addiction warning, Artificial-intelligence-developed sleep warning, Artificial-intelligence-developed mental health harms to young people warning, Artificial-intelligence-developed warning that social media has not been proven safe
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 29 Years
Enrollment
1,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 21, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

NCT05734313
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes
Interventions
Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM)
Behavioral · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 21, 2026, 1:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Changes in Brain Function Through Repeated Emotion Regulation Training

NCT04265859
View directory record Official record
Conditions
Depression
Interventions
Cognitive Behavioral Training, Mindfulness
Behavioral
Lead sponsor
Michael Stevens
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

NCT03307070
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Family Nurture Intervention in the NICU

NCT02710474
View directory record Official record
Conditions
Premature Birth, Obstetric Labor, Premature
Interventions
Family Nurture Intervention, Standard Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
26 Weeks to 34 Weeks
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

NCT04521478
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo, Quetiapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

NCT05837104
View directory record Official record
Conditions
Bipolar I Disorder, Depression, Anxiety, Stress
Interventions
Magnesium vitamin B6, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

NCT03765138
View directory record Official record
Conditions
PTSD, MDD
Interventions
PE/Pramipexole
Combination Product
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 1:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the H.O.O.V.E.S. Healing Intensives Program

NCT06300255
View directory record Official record
Conditions
Anxiety, PTSD, Depression
Interventions
H.O.O.V.E.S. Healing Intensives
Behavioral
Lead sponsor
VA Salt Lake City Health Care System
Federal
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Depression

NCT01341925
View directory record Official record
Conditions
Depression
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder

NCT00595387
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Supportive Psychotherapy, Cognitive Behavioral Therapy (CBT)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Microcurrent Neurofeedback as an Adjunct to Standard Care for Substance Use Disorders

NCT07737652
View directory record Official record
Conditions
Depression, Anxiety, Substance Use Disorder (SUD), Post Traumatic Stress Disorder
Interventions
Microcurrent Neurofeedback (MCN), Standard Care for Substance Use Disorder
Device · Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment

NCT01903447
View directory record Official record
Conditions
Internalizing Psychopathologies (IPs) Depression and Anxiety
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 21, 2026, 1:38 PM EDT
Not listed Phase 3 Interventional

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

NCT03396068
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
NRX-101, Lurasidone HCl
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Hollywood, Florida • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

NCT02196506
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Placebo + ADT, Brexpiprazole +ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Beverly Hills, California • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

NCT03665038
View directory record Official record
Conditions
Post Partum Depression
Interventions
Brexanolone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 17 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Tempe, Arizona • North Little Rock, Arkansas • Miramar, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 1:38 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes

NCT00553917
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 21, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal Spray
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
51
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Parenting Skills Group for Mothers With Postpartum Depression

NCT05772897
View directory record Official record
Conditions
Postpartum Depression
Interventions
Circle of Security Parenting program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 1:38 PM EDT
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 1:38 PM EDT